RIPK4 and neoplasm: Given that a hallmark feature of TNBC is an “immune-cold” microenvironment where lymphocyte infiltration into the tumor is limited [15, 34, 35], our data indicate that targeting RIPK4 may foster an increase abundance of lymphocytes at the tumor site.